Arcturus Therapeutics Holdings

ARCT

Healthcare

$8.41-1.87%vs prev close

$5.85

$24.17

52W RangeNear 52W Low

+0.91 (+11.07%)Past 1M

Price

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

2,686,787

Portfolio Weight

0.18%

in ETF 1.91%

Est. Value

$23M

30D Net

+$69K

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

None

Strong Buy

Buy

Hold

Analyst Targets

avg.

$23.30

vs Current ▲ +177.1% upside

Current$8.41

Low ~ High$8.00 ~ $68.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

B. Riley Securities

Buy

$22.00

+161.59%

$6.55

Upgrade

2026-03-18

Citigroup

Buy

$21.00

+149.70%

$7.25

Maintain

2026-03-05

Citigroup

Neutral

$8.00

-4.88%

$7.58

Maintain

2026-03-04

Piper Sandler

Overweight

$25.00

+197.27%

$7.58

Maintain

2026-03-04

Citigroup

Neutral

$7.00

-16.77%

$6.61

Maintain

2026-01-06

1 / 1

Avg Target

$23.30

vs Current ▲ +177.1% upside

None

13 analysts

Strong Buy 2Buy 8Hold 3

Low $8.00

Current $8.41

High $68.00

Firm	Position	Target	Upside	Close	Action	Date
B. Riley Securities	Buy	$22.00	+161.59%	$6.55	Upgrade	26.03.18
Citigroup	Buy	$21.00	+149.70%	$7.25	Maintain	26.03.05
Citigroup	Neutral	$8.00	-4.88%	$7.58	Maintain	26.03.04
Piper Sandler	Overweight	$25.00	+197.27%	$7.58	Maintain	26.03.04
Citigroup	Neutral	$7.00	-16.77%	$6.61	Maintain	26.01.06

1 / 1

Price Information

Previous Close$8.57

Open$8.68

Day Range$8.22 - $8.83

52-Week Range$5.85 - $24.17

1-Year Change-23.20%

Trading Volume

Volume408,112

Avg Volume (3mo)450,111

Valuation

Market Cap239.0M

Book Value$7.53

Shares Outstanding28,423,069

Financials

Revenue (TTM)82.0M

Net Income-65,783,000

EPS$-2.40

EBITDA-73,235,000

Profitability

P/E Ratio-

P/B Ratio1.12

Return on Equity (ROE)-28.92%

Return on Assets (ROA)-15.50%

Profit Margin-80.19%

EV/EBITDA-0.45

Beta2.42

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)45.98

Company Overview

Arcturus Therapeutics Holdings is a biotechnology company focused on developing vaccines for infectious diseases and therapeutics for rare liver and respiratory diseases. They utilize LUNAR lipid-mediated delivery and STARR mRNA technology platforms to advance candidates like ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis. The company is also developing COVID-19 vaccines and influenza vaccines, with several candidates in various stages of clinical trials.

P/B

1.12

Price-to-Book

ROE

-28.9%

Persistent loss

Beta

2.42

Extreme volatility

RSI(14)

46.0

Neutral

AI-generated summary. Not investment advice.